# Cannabidiol Cortical Excitability Clinical Trial > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabidiol-cortical-excitability-clinical-trial-data/ > **Published:** 2026-04-25T10:23:18-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:20:28-04:00 > **Clinical Summary:** Explore cannabidiol cortical excitability clinical trial data revealing CBD's effects on brain excitability and seizure control in healthy adults. --- #### Clinical Takeaway In a controlled crossover trial of healthy males, CBD at both low and high single doses failed to directly reduce cortical excitability compared to placebo, suggesting its anti-seizure effects may depend heavily on pharmacokinetic interactions with co-administered medications like clobazam rather than acting alone on the brain. Clinicians should not assume CBD provides standalone neuroprotection or seizure suppression outside of its established adjunctive context. These findings reinforce the importance of polypharmacy considerations when evaluating CBD’s role in [epilepsy management](https://cedclinic.com/cannabinoid-like-compound-seizure-reduction/). ### #10 Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial. **Citation:** Gorbenko Andriy A et al. *Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.* [Clinical pharmacology](https://cedclinic.com/temporary-placement-bromazolam-schedule-i/) and therapeutics. 2026. PMID: 40836528. **Study type:** Journal Article, Randomized Controlled Trial  |  **Topic area:** Cannabidiol  |  **CED Score:** 11 Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0 Why This Matters This study clarifies that CBD’s clinical efficacy in seizure management may depend primarily on drug-drug interactions rather than direct effects on neuronal excitability, which has important implications for patient selection and polypharmacy considerations in epilepsy treatment. Understanding CBD’s mechanism of action is essential for clinicians to optimize dosing strategies and predict efficacy in patients not taking interacting medications like clobazam. These findings help distinguish between CBD’s pharmacokinetic contributions and any potential direct anti-seizure properties, enabling more rational therapeutic decisions in managing drug-resistant epilepsy. **Abstract:** Cannabidiol (CBD) is approved as an adjunctive treatment of seizures associated with [Dravet syndrome](https://cedclinic.com/cannabidiol-for-epilepsy-treatment-rare-forms/), Lennox-Gastaut Syndrome, and tuberous sclerosis. Its therapeutic and [adverse effects](https://cedclinic.com/physician-concerns-cannabis-health-effects-washington/) are thought to arise, at least partly, from a pharmacokinetic interaction with clobazam, another anti-seizure medication (ASM). The goal of this study was to evaluate the intrinsic anti-epileptic and sedative properties of CBD. A randomized, double-blind, placebo-controlled, 3-way crossover trial was conducted in 25 healthy males. On each visit, single doses of 30 mg CBD, 700 mg CBD, or placebo were administered orally. The effects of CBD on cortical excitability were measured using transcranial magnetic stimulation (TMS) combined with electromyography (EMG) and electroencephalography (EEG). Sedative properties were assessed using a validated CNS test battery. Pharmacokinetic sampling was performed. Data were analyzed using a mixed-effects model. CBD did not have significant effects on single pulse and paired pulse TMS-EMG parameters, compared to placebo. Some significant clusters were seen on paired pulse TMS-EEG at 3 hours post-dose for 30 mg CBD, and at 3 and 5 hours post-dose for 700 mg CBD. CBD did not have significant effects on any tests assessing its sedative properties. These results suggest that CBD may lack intrinsic anti-epileptic and sedative properties and that its effects could be primarily a product of interactions with other drugs, notably clobazam. Clinical Perspective This well-designed crossover study challenges a common assumption about cannabidiol’s mechanism of action by demonstrating that CBD does not directly suppress cortical excitability in the way traditional antiepileptic drugs do, suggesting that its clinical efficacy in seizure disorders may rely more heavily on pharmacokinetic interactions with concurrent medications like clobazam rather than intrinsic neuronal effects. While the study’s controlled design is a strength, the relatively small sample size and focus on surrogate markers of excitability (rather than actual seizure outcomes) warrant caution in extrapolating findings to real-world clinical populations with heterogeneous seizure types and comorbidities. Additionally, the study cannot entirely exclude indirect mechanisms or effects mediated through non-cortical brain regions relevant to seizure suppression. For clinicians, this research underscores the importance of understanding CBD not as a monotherapy replacement for conventional antiepileptics but rather as an agent whose benefit may be optimized when used alongside compatible medications, and it  |   |  Further Reading CED Clinic Blog[5 Surprising Benefits of Cannabidiol Anxiety Treatment](https://cedclinic.com/cannabidiol-anxiety-treatment-benefits/) CED Clinic Blog[Cannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years](https://cedclinic.com/cannabis-beverage-substitution-alcohol-new-york-five-years/) Research Digest[Daily Digest 2026-03-07](https://cedclinic.com/adolescent-cannabis-psychiatric-outcomes-2026-digest/) [View on PubMed ↗](https://pubmed.ncbi.nlm.nih.gov/40836528/)[Full Text ↗](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12746520/)[DOI ↗](https://doi.org/10.1002/cpt.70038) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabidiol & Cortical Excitability: Clinical Trial Findings](https://cedclinic.com/cannabidiol-lacks-intrinsic-anti-epileptic-properties-trial/) Detailed findings from [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) investigating cannabidiol's effects on cortical excitability and seizure management. [Read More](https://cedclinic.com/cannabidiol-lacks-intrinsic-anti-epileptic-properties-trial/) [Cannabinoid Clinical Trials: CBD & Cortical Excitability](https://cedclinic.com/cbd-anti-seizure-properties-cortical-excitability-trial/) Explore [clinical trial](https://cedclinic.com/marijuana-reclassification-impact-cannabis-companies/) data on CBD's role in modulating cortical excitability and its implications for epilepsy treatment. [Explore Study](https://cedclinic.com/cbd-anti-seizure-properties-cortical-excitability-trial/) [Cannabidiol Cortical Excitability Clinical Trial](https://cedclinic.com/cannabidiol-cortical-excitability-clinical-trial-data/) An overview of a randomized controlled trial assessing cannabidiol's direct effects on cortical excitability in healthy subjects. [Learn More](https://cedclinic.com/cannabidiol-cortical-excitability-clinical-trial-data/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Cannabidiol%20%26%20Cortical%20Excitability%3A%20Clinical%20Trial%20Evidence&url=https%3A%2F%2Fcedclinic.com%2Fcannabidiol-cortical-excitability-clinical-trial%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabidiol-cortical-excitability-clinical-trial%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Cannabidiol%20%26%20Cortical%20Excitability%3A%20Clinical%20Trial%20Evidence%20https%3A%2F%2Fcedclinic.com%2Fcannabidiol-cortical-excitability-clinical-trial%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).